Frydman Galit H, Ellett Felix, Van Cott Elizabeth M, Hayden Douglas, Majmudar Maulik, Vanderburg Charles R, Dalzell Haley, Padmanabhan Divya L, Davis Nick, Jorgensen Julianne, Toner Mehmet, Fox James G, Tompkins Ronald G
Division of Comparative Medicine, Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA.
BioMEMS Resource Center, Department of Surgery, Massachusetts General Hospital, Boston, MA.
Crit Care Explor. 2019 Aug 20;1(8):e0024. doi: 10.1097/CCE.0000000000000024. eCollection 2019 Aug.
Determining whether a patient has taken a direct oral anticoagulant (DOAC) is critical during the periprocedural and preoperative period in the emergency department. However, the inaccessibility of complete medical records, along with the generally inconsistent sensitivity of conventional coagulation tests to these drugs, complicates clinical decision making and puts patients at risk of uncontrollable bleeding. In this study, we evaluate the utility of inhibitor-II-X (i-II-X), a novel, microfluidics-based diagnostic assay for the detection and identification of Factor Xa inhibitors (FXa-Is) in an acute care setting.
First-in-human, 91-patient, single-center retrospective pilot study.
Emergency room.
Adult patients admitted into the emergency department, which received any clinician-ordered coagulation test requiring a 3.2% buffered sodium citrate blood collection tube.
None.
Plasma samples from patients admitted to the emergency department were screened for the use of FXa-Is, including apixaban and rivaroxaban, within the past 24 hours using our new i-II-X microfluidic test. i-II-X results were then compared with results from conventional coagulation tests, including prothrombin time (PT) and international normalized ratio (INR), which were ordered by treating clinicians, and an anti-Xa assay for rivaroxaban. The i-II-X test detected DOACs in samples collected from the emergency department with 95.20% sensitivity and 100.00% specificity. Unlike PT and INR, i-II-X reliably identified patients who had prolonged clotting times secondary to the presence of a FXa-I.
The i-II-X test overcomes the limitations of currently available coagulation tests and could be a useful tool by which to routinely screen patients for DOACs in emergency and critical care settings. Our new diagnostic approach is particularly relevant in clinical situations where medical records may be unavailable, or where precautions need to be taken prior to invasive interventions, such as specific reversal agent administration.
在急诊科围手术期和术前确定患者是否服用了直接口服抗凝剂(DOAC)至关重要。然而,完整病历难以获取,加上传统凝血试验对这些药物的敏感性普遍不一致,使临床决策变得复杂,并使患者面临无法控制出血的风险。在本研究中,我们评估了抑制剂-II-X(i-II-X)的效用,这是一种基于微流控技术的新型诊断检测方法,用于在急性护理环境中检测和识别Xa因子抑制剂(FXa-Is)。
首例人体、91例患者的单中心回顾性试点研究。
急诊室。
入住急诊科的成年患者,接受了任何临床医生要求的需要使用3.2%柠檬酸钠缓冲采血试管的凝血试验。
无。
使用我们新的i-II-X微流控试验,对入住急诊科患者的血浆样本进行筛查,以确定过去24小时内是否使用了FXa-Is,包括阿哌沙班和利伐沙班。然后将i-II-X结果与传统凝血试验结果进行比较,传统凝血试验包括治疗临床医生所要求的凝血酶原时间(PT)和国际标准化比值(INR),以及利伐沙班的抗Xa检测。i-II-X试验在急诊科采集的样本中检测DOACs的灵敏度为95.20%,特异性为100.00%。与PT和INR不同,i-II-X能够可靠地识别因存在FXa-I而凝血时间延长的患者。
i-II-X试验克服了现有凝血试验的局限性,可能成为在急诊和重症护理环境中对患者进行DOACs常规筛查的有用工具。我们的新诊断方法在病历可能无法获取或在进行侵入性干预(如给予特定逆转剂)之前需要采取预防措施的临床情况下尤为重要。